DexCom, Inc.

DexCom, Inc. has achieved a new 52-week high, despite facing a challenging year with a notable stock decline. The company maintains strong financial health, highlighted by a net-debt-free status and impressive profit growth. Its operational efficiency is reflected in record cash flow and attractive valuation metrics.

DexCom, Inc. has experienced notable stock performance, significantly outperforming the S&P 500 over the past month and year-to-date. The company maintains a strong financial position, highlighted by its net-debt-free status and high return on capital employed. Promoter confidence is also increasing, indicating a positive outlook.

DexCom, Inc. has recently experienced a decline in stock price, reflecting ongoing market pressures. Over the past year, the company has faced challenges, with a notable drop in returns compared to the S&P 500. However, its long-term performance remains strong, significantly outperforming the index over the past decade.

DexCom, Inc. faced a significant stock decline today, reaching an intraday low. Over the past month, the company has experienced a pronounced decrease, contrasting with the S&P 500's performance. Despite these challenges, DexCom retains a solid financial foundation and strong profitability metrics.

DexCom, Inc. has experienced notable stock fluctuations, closing at 74.38, with a 52-week range of 54.11 to 90.00. Recent performance indicators show mixed signals, with some bullish trends alongside short-term challenges. Year-to-date, the stock has outperformed the S&P 500, but longer-term returns remain negative.

DexCom, Inc. faced notable stock volatility on October 31, 2025, with a significant decline. Over the past week and month, the company's performance has weakened, contrasting with the S&P 500. Despite this, DexCom maintains a strong financial profile, including high return on equity and robust sales growth.

DexCom, Inc. has reached a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company, valued at approximately USD 30.66 billion, has a high P/E ratio and does not offer dividends. Its financial metrics indicate a conservative leverage approach and effective management of shareholder equity.

DexCom, Inc. has experienced a valuation adjustment, with its stock price declining significantly over the past year. The company reports a P/E ratio of 64 and an EV to EBITDA ratio of 39.43, indicating a premium valuation compared to competitors. Its operational efficiency is highlighted by a ROCE of 31.15% and ROE of 23.61%.

DexCom, Inc. has recently adjusted its valuation grade, moving from very expensive to expensive. Key financial metrics include a P/E ratio of 64, a price-to-book value of 15.03, and strong returns on capital employed and equity. The company also reports significant long-term growth in net sales and operating profit.

DexCom, Inc. has recently adjusted its valuation, with a current P/E ratio of 64 and a Price to Book Value of 15.03. Compared to peers like Edwards Lifesciences and Agilent Technologies, DexCom's metrics suggest a stronger growth perception. However, its year-to-date performance shows a decline against the S&P 500.

DexCom, Inc. has recently revised its stock evaluation, currently priced at $69.51 after a notable shift. The company has experienced significant volatility over the past year, with a 52-week high of $93.25 and a low of $57.52. Its performance has lagged behind the S&P 500 across various time frames.